Simvastatin regulates the proliferation, apoptosis, migration and invasion of human acute myeloid leukemia cells via miR-19a-3p/HIF-1α axis

References

• Izzi V, Lakkala J, Devarajan R, et al. Expression of a specific extracellular matrix signature is a favorable prognostic factor in acute myeloid leukemia. Leuk Res Rep. 2018;9:9–13. 2017/12/23.
   PubMedGoogle Scholar
• Ganapule A, Nemani S, Korula A, et al. Allogeneic stem cell transplant for acute myeloid leukemia: evolution of an effective strategy in India. J Glob Oncol. 2017;3(6):773–781. 2017/12/16.
   PubMed Web of Science ®Google Scholar
• Fontana MC, Marconi G, Feenstra JDM, et al. Chromothripsis in acute myeloid leukemia: biological features and impact on survival. Leukemia. 2018;32(7):1609–1620. 2018/02/24.
   PubMed Web of Science ®Google Scholar
• Campbell MJ, Esserman LJ, Zhou Y, et al. Breast cancer growth prevention by statins. Cancer Res. 2006;66(17):8707–8714. 2006/09/05.
   PubMed Web of Science ®Google Scholar
• Fromigué O, Haÿ E, Modrowski D, et al. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 2006 Feb 14;13(11):1845–1856.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zheng X, Lytle RA, et al. Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells. J Neurochem. 2004 Mar 20;89(1):168–178.
   PubMed Web of Science ®Google Scholar
• Lee J, Lee SH, Hur KY, et al. Statins and the risk of gastric cancer in diabetes patients. BMC Cancer. 2012 Dec 14;12(1):596.
   PubMed Web of Science ®Google Scholar
• de Jonge-peeters SD, van der Weide K, Kuipers F, et al. Variability in responsiveness to lovastatin of the primitive CD34+ AML subfraction compared to normal CD34+ cells. Ann Hematol. 2009;88(6):573–580. 2008/11/13.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Lee I, Lee J, et al. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer. Br J Cancer. 2014 Jun 20;111(3):497–505.
   PubMed Web of Science ®Google Scholar
• Dimitroulakos J, Nohynek D, Backway KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood. 1999 Feb 09;93(4):1308–1318.
   PubMed Web of Science ®Google Scholar
• Newman A, Clutterbuck RD, Powles RL, et al. Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin. Leukemia. 1994 Nov 01;8:2023–2029.
   PubMed Web of Science ®Google Scholar
• van der Weide K, de Jonge-peeters SD, Kuipers F, et al. Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+acute myeloid leukemia samples. Clin Cancer Res off J Am Assoc Cancer Res. 2009 Apr 23;15(9):3076–3083.
   PubMed Web of Science ®Google Scholar
• van der Weide K, Korthuis PM, Kuipers F, et al. Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation. Leukemia. 2012;26(4):845–848. 2011/09/21.
   PubMed Web of Science ®Google Scholar
• Newman A, Clutterbuck RD, DeLord C, et al. The sensitivity of leukemic bone marrow to simvastatin is lost at remission: a potential purging agent for autologous bone marrow transplantation. J Investig Med Copy Clin Invest 1995 Jun 01; 43: 269–274.
   Google Scholar
• Dai Y, Khanna P, Chen S, et al. Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood. 2007 Feb 01;109(10):4415–4423.
   PubMed Web of Science ®Google Scholar
• Gmeiner WH, Jennings-Gee J, Stuart CH, et al. Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway. Leuk Res. 2015;39(2):229–235. 2014/12/17.
   PubMed Web of Science ®Google Scholar
• Newman A, Clutterbuck RD, Powles RL, et al. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma. 1997;24(5–6):533–537. 1997/02/01.
   PubMed Web of Science ®Google Scholar
• Lishner M, Bar-Sef A, Elis A, et al. Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Investig Med Copy Clin Invest 2001 Aug 02; 49(4): 319–324.
   Google Scholar
• Clutterbuck RD, Millar BC, Powles RL, et al. Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. Br J Haematol. 1998 Aug 08;102(2):522–527.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016;231(1):25–30. 2015/06/03.
   PubMed Web of Science ®Google Scholar
• Gabra MM, Salmena L. microRNAs and acute myeloid leukemia chemoresistance: a mechanistic overview. Front Oncol. 2017 Nov 23;7:255.
   PubMed Web of Science ®Google Scholar
• Jonas S, Izaurralde E. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet. 2015 Jun 17;16(7):421–433.
   PubMed Web of Science ®Google Scholar
• Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin Chem. 2009 Feb 28;55(4):623–631.
   PubMed Web of Science ®Google Scholar
• Liu J, Zheng M, Tang YL, et al. MicroRNs, an active and versatile group in cancers. Int J Oral Sci. 2011 Oct 21 ;3(4):165–175.
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005 Jun 10;435(7043):834–838.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zou Y, Lin L, et al. Identification of serum miR-34a as a potential biomarker in acute myeloid leukemia. Cancer Biomarkers. 2018 Jun 28;22(4):799–805.
   PubMed Web of Science ®Google Scholar
• Ding Q, Wang Q, Ren Y, et al. MicroRNA-126 attenuates cell apoptosis by targeting TRAF7 in acute myeloid leukemia cells. Biochem Cell Biol. 2018 Jun 26;96(6):840–846.
   PubMed Web of Science ®Google Scholar
• Wang Z, Luo H, Fang Z, et al. MiR-204 acts as a potential therapeutic target in acute myeloid leukemia by increasing BIRC6-mediated apoptosis. BMB Rep. 2018 May 17;51(9):444–449.
   PubMed Web of Science ®Google Scholar
• Cheng J, Yang A, Cheng S, et al. Circulating miR-19a-3p and miR-483-5p as novel diagnostic biomarkers for the early diagnosis of gastric cancer. Med Sci Monit. 2020 Jun 04;26:e923444.
   PubMed Web of Science ®Google Scholar
• Yu FB, Sheng J, Yu JM, et al. MiR-19a-3p regulates the Forkhead box F2-mediated Wnt/β-catenin signaling pathway and affects the biological functions of colorectal cancer cells. World J Gastroenterol. 2020 Feb 28;26(6):627–644.
   PubMed Web of Science ®Google Scholar
• Bai R, Cui Z, Ma Y, et al. The NF-κB-modulated miR-19a-3p enhances malignancy of human ovarian cancer cells through inhibition of IGFBP-3 expression. Mol Carcinog. 2019 Sept 13;58(12):2254–2265.
   PubMed Web of Science ®Google Scholar
• Wa Q, Li L, Lin H, et al. Downregulation of miR-19a-3p promotes invasion, migration and bone metastasis via activating TGF-β signaling in prostate cancer. Oncol Rep. 2018;39:81–90. 2017/11/16.
   PubMed Web of Science ®Google Scholar
• Cardiac differentiation of bone-marrow-resident c-kit+ stem cells by L-carnitine increases through secretion of VEGF. IL6, IGF-1, and TGF-β as clinical agents in cardiac regeneration. J Biosci. 2020 Dec;45(1):1.
   PubMed Web of Science ®Google Scholar
• Wu F, Yin C, Qi J, et al. miR-362-5p promotes cell proliferation and cell cycle progression by targeting GAS7 in acute myeloid leukemia. Hum Cell. 2020;33(2):405–415.
   PubMed Web of Science ®Google Scholar
• Fathi E, Farahzadi R, Valipour B. Alginate/gelatin encapsulation promotes NK cells differentiation potential of bone marrow resident C-kit+ hematopoietic stem cells. Int J Biol Macromol. 2021 Apr 30;177::317–327.
   PubMed Web of Science ®Google Scholar
• Steitz AM, Steffes A, Finkernagel F, et al. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C. Cell Death Dis. 2020;11(4):249. Published 2020 Apr 20.
   PubMed Web of Science ®Google Scholar
• Pan Y, Jin K, Xie X, et al. MicroRNA-19a-3p inhibits the cellular proliferation and invasion of non-small cell lung cancer by downregulating UBAP2L. Exp Ther Med. 2020 Aug 09;20:2252–2261.
   PubMed Web of Science ®Google Scholar
• Fathi E, Sanaat Z, Farahzadi R. Mesenchymal stem cells in acute myeloid leukemia: a focus on mechanisms involved and therapeutic concepts. Blood Res. 2019 Sep 1;54(3):165–174.
   PubMed Web of Science ®Google Scholar
• A general view of CD. 33+ leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy. Blood Res. 2020 Mar 1;55(1): 10–16.
   PubMed Web of Science ®Google Scholar
• Zhou H, Jia X, Yang F, et al. miR-148a-3p suppresses the progression of acute myeloid leukemia via targeting cyclin-dependent kinase 6 (CDK6). Bioengineered. 2021;12(1):4508–4519.
   PubMed Web of Science ®Google Scholar
• Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004 Jan 17;103(10):3669–3676.
   PubMed Web of Science ®Google Scholar
• Jang J, Lee J, Jang JH, et al. Anti-leukemic effects of simvastatin on NRAS(G12D) mutant acute myeloid leukemia cells. Mol Biol Rep. 2019 Aug 28;46(6):5859–5866.
   PubMed Web of Science ®Google Scholar
• Ahmed TA, Hayslip J, Leggas M. Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition. Leuk Res. 2014;38(11):1350–1357.
   PubMed Web of Science ®Google Scholar
• He XP, Chen P, Yang K, et al. Overexpression of miR-21 is involved in acute monocytic leukemia-associated angiogenesis by targeting IL-12. Mol Med Rep. 2018 Aug 15;18:4122–4128.
   PubMed Web of Science ®Google Scholar
• Zhu B, Xi X, Liu Q, et al. MiR-9 functions as a tumor suppressor in acute myeloid leukemia by targeting CX chemokine receptor 4. Am J Transl Res. 2019 Jul 18;11:3384–3397.
   PubMed Web of Science ®Google Scholar
• Yu FB, Sheng J, Yu JM, et al. MiR-19a-3p regulates the Forkhead box F2-mediated Wnt/β-catenin signaling pathway and affects the biological functions of colorectal cancer cells. World J Gastroenterol. 2020;26(6):627–644.
   PubMed Web of Science ®Google Scholar
• Wa Q, Li L, Lin H, et al. Downregulation of miR‑19a‑3p promotes invasion, migration and bone metastasis via activating TGF‑β signaling in prostate cancer. Oncol Rep. 2018;39(1):81–90.
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu Y, Zhang J. Silencing of miR-19a-3p enhances osteosarcoma cells chemosensitivity by elevating the expression of tumor suppressor PTEN. Oncol Lett. 2019 Jan 19;17:414–421.
   PubMed Web of Science ®Google Scholar
• Zhe N, Chen S, Zhou Z, et al. HIF-1α inhibition by 2-methoxyestradiol induces cell death via activation of the mitochondrial apoptotic pathway in acute myeloid leukemia. Cancer Biol Ther. 2016;17(6):625–634.
   PubMed Web of Science ®Google Scholar